Investor Relations

Investor Overview Image

Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel antibodies that are directed towards diseases that involve protein misfolding or cell adhesion. These potential therapies have a number of indications including AL and AA forms of amyloidosis (NEOD001), Parkinson’s disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in autoimmune diseases and cancers (PRX003).

NASDAQ: PRTA
$ 26.26
1.03 (3.77%)

Day High: 27.61
Day Low:  24.08
Volume:    503,400
4:00 PM ET
Apr 15, 2014

Delayed ~20 min., by eSignal.

Press Releases

Apr 8, 2014
Mar 18, 2014